Prothrombin Complex Concentrate Market Report 2026

Prothrombin Complex Concentrate Market Overview

• Prothrombin Complex Concentrate market size has reached to $1.38 billion in 2025 • Expected to grow to $1.96 billion in 2030 at a compound annual growth rate (CAGR) of 7.2% • Growth Driver: Rising Prevalence Of Bleeding Disorders Driving The Growth Of The Market Due To Increasing Genetic Mutations and Inherited Conditions • Market Trend: Development Of Innovative Formulations In The Market • North America was the largest region in 2025.

What Is Covered Under Prothrombin Complex Concentrate Market?

Prothrombin complex concentrate (PCC) is a medication containing clotting factors used to treat or prevent bleeding in patients with coagulation disorders. It is administered intravenously to rapidly restore clotting factor levels in conditions such as hemophilia, warfarin reversal, and severe bleeding episodes. The main product types in prothrombin complex concentrate include 3-factor prothrombin complex concentrates (3F-PCC), 4-factor prothrombin complex concentrates (4F-PCC), and other products. 3-factor prothrombin complex concentrates (3F-PCC) are blood products containing clotting factors II, IX, and X, used to manage bleeding without the need for factor VII supplementation. These are indicated for various conditions, including hemorrhagic episodes in factor IX deficiency (hemophilia B), trauma, life-threatening coagulopathy with acute bleeding, warfarin-associated acute life-threatening bleeding, and non-warfarin anticoagulant reversal in the presence of acute bleeding. Routes of administration are intravenous (IV), subcutaneous, and intramuscular injections, and are used in hospitals, ambulatory surgical centers, specialty clinics, and other healthcare facilities.

What Is The Prothrombin Complex Concentrate Market Growth Forecast?

The prothrombin complex concentrate market size is expected to see strong growth in the next few years. It will grow to $1.96 billion in 2030 at a compound annual growth rate (CAGR) of 7.2%. The growth in the forecast period can be attributed to increasing demand for fast-acting coagulation therapies, rising investments in recombinant factor development, expansion of trauma care facilities, growing focus on patient safety in anticoagulant management, increasing adoption of standardized bleeding protocols. Major trends in the forecast period include increasing adoption of four-factor pcc products, rising use of pcc for rapid anticoagulant reversal, growing demand for emergency bleeding management solutions, expansion of recombinant coagulation products, enhanced focus on rapid-acting hemostatic therapies.

Global Prothrombin Complex Concentrate Market Segmentation

1) By Product: 3-Factor Prothrombin Complex Concentrates, 4-Factor Prothrombin Complex Concentrates, Other Products 2) By Indication: Haemorrhagic Episodes In Factor IX Deficiency (Haemophilia B), Trauma, Life-Threatening Coagulopathy With Acute Bleeding, Warfarin-Associated Acute, Life-Threatening Bleeding, Non-Warfarin Anticoagulant Reversal With Acute Bleeding 3) By Route Of Administration: Intravenous, Intravenous Infusion Variants, Intravenous Bolus Administration 4) By End-Use: Hospital And Ambulatory Surgical Centers, Specialty Clinics, Other End Users Subsegments: 1) By 3-Factor PCC Type: Low-Dose 3-Factor Prothrombin Complex Concentrates (PCC), High-Dose 3-Factor Prothrombin Complex Concentrates (PCC), Lyophilized 3-Factor Prothrombin Complex Concentrates (PCC) 2) By 4-Factor PCC Typ: Low-Dose 4-Factor Prothrombin Complex Concentrates (PCC), High-Dose 4-Factor Prothrombin Complex Concentrates (PCC), Activated 4-Factor Prothrombin Complex Concentrates (PCC) 3) By Other Products: Recombinant Coagulation Factor Complexes, Plasma-Derived Coagulation Factor Complexes, Combination Therapy Products

What Are The Drivers Of The Prothrombin Complex Concentrate Market?

The increasing prevalence of bleeding disorders is expected to propel the growth of the prothrombin complex concentrate market going forward. Bleeding disorders are medical conditions where the blood does not clot properly, leading to excessive bleeding due to missing or malfunctioning clotting factors or platelets. Bleeding disorders are increasing mainly due to the rising prevalence of genetic conditions such as hemophilia, increasing cases of liver disease, the growing use of anticoagulant medications, and a higher incidence of vitamin K deficiencies. Prothrombin complex concentrate helps treat bleeding disorders by rapidly replenishing clotting factors, which are essential for effective blood coagulation and hemostasis. For instance, in October 2024, according to a report published by the World Federation of Hemophilia, a Canada-based non-profit organization, in 2023, there were 179,703 reported cases of hemophilia A. Among these, 162,040 cases (90%) were males, and 6,990 cases were females, while 10,673 cases (6%) did not specify the patient’s sex. Therefore, the increasing prevalence of bleeding disorders is driving the growth of the prothrombin complex concentrate industry. The growing prescription rate of anticoagulants is expected to propel the growth of the prothrombin complex concentrate market going forward. An anticoagulant is a substance that prevents or reduces blood clot formation by inhibiting coagulation factors or platelet aggregation. The growing prescription rate of anticoagulants is due to the rising prevalence of cardiovascular diseases, an aging population, expanding clinical indications, improved screening programs, and advancements in anticoagulant therapy. Prothrombin complex concentrate counteracts the effects of anticoagulants by rapidly replenishing clotting factors and restoring hemostasis in patients with excessive bleeding or urgent surgical needs. For instance, in June 2025, according to the Northern Ireland Statistics and Research Agency (NISRA), a UK-based government department, in 2024/25, 64,000 people received oral anticoagulants, marking a 3.8% rise compared to the previous year, with 3.3% of the population using these medications overall. Therefore, the growing prescription rate of anticoagulants is driving the growth of the prothrombin complex concentrate industry.

Key Players In The Global Prothrombin Complex Concentrate Market

Major companies operating in the prothrombin complex concentrate market are Pfizer Inc., Takeda Pharmaceutical Company Limited, CSL Behring GmbH, Baxter International Inc, Grifols S.A., Octapharma AG, Kedrion S.p.A, Green Cross Corporation, Shanghai RAAS Blood Products Co. Ltd, LFB Group, Hualan Biological Engineering Chongqing Co. Ltd., Sanquin Blood Supply Foundation, Bio Products Laboratory Ltd BPL, Prothya Biosolutions B.V., China Biologic Products Holdings Inc., Intas Pharmaceuticals Ltd, Biotest AG, Octapharma Plasma, Kamada Ltd, SK Plasma Co. Ltd, Reliance Life Sciences, Bharat Serums And Vaccines Limited

Global Prothrombin Complex Concentrate Market Trends and Insights

Major companies operating in the prothrombin complex concentrate market are developing innovative formulations such as lyophilized powder to enhance stability, improve storage, and simplify administration. The lyophilized powder is a freeze-dried formulation that removes water to increase shelf life and maintain potency. This allows for better storage conditions and rapid reconstitution for emergency use. For instance, in July 2023, Octapharma USA Inc., a US-based biotechnology company, received FDA approval for Balfaxar, a four-factor prothrombin complex concentrate (4F-PCC) for urgent warfarin reversal in surgeries and invasive procedures. The approval was based on the LEX-209 trial, which showed 94.6% hemostatic efficacy, proving it as effective as Kcentra. This advancement underscores the industry's focus on improving coagulation therapies to enhance patient outcomes in critical care settings.

Regional Outlook

North America was the largest region in the prothrombin complex concentrate market in 2025. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Prothrombin Complex Concentrate Market?

The prothrombin complex concentrate market consists of sales of activated PCC, recombinant coagulation factors, combination hemostatic agents, warfarin reversal, and emergency coagulation therapy products. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Prothrombin Complex Concentrate Market Report 2026?

The prothrombin complex concentrate market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the prothrombin complex concentrate industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.